Monoclonal Antibodies

Monoclonal Antibodies

Global Monoclonal Antibodies Market to Reach US$266.8 Billion by 2030

The global market for Monoclonal Antibodies estimated at US$168.8 Billion in the year 2023, is expected to reach US$266.8 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2023-2030. Human-sourced Monoclonal Antibodies, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and reach US$105.2 Billion by the end of the analysis period. Growth in the Humanized Monoclonal Antibodies segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$45.4 Billion While China is Forecast to Grow at 11.2% CAGR

The Monoclonal Antibodies market in the U.S. is estimated at US$45.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$62.1 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.4% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.8% CAGR.

Monoclonal Antibodies  - Key Trends and Drivers

Antibodies, crucial components of the immune system, are Y-shaped proteins produced by B lymphocytes in response to pathogen invasion. These molecules play a pivotal role in immunological defense, with each antibody tailored to recognize and bind to specific antigens, a characteristic that underpins their therapeutic potential in modern medicine. Monoclonal antibodies (mAbs) represent a significant sector in the biopharmaceutical industry, characterized by rapid growth and substantial contributions to medical treatments, particularly in the areas of oncology, autoimmune diseases, and infectious diseases. This growth is driven by several key factors and supported by emerging trends that are shaping the future of therapeutic monoclonal antibodies. The future of monoclonal antibodies looks promising with continued advancements in science and technology driving the market forward. As research deepens our understanding of diseases at the molecular level, mAbs are expected to play an increasingly vital role in medicine. Moreover, the integration of AI and machine learning in drug development pipelines is likely to enhance the specificity and functionality of monoclonal antibodies, potentially leading to more effective therapies with fewer side effects.

The continuous evolution of biotechnological methods, including better cell line engineering and enhanced protein expression systems, has significantly improved the development and production of monoclonal antibodies. These advancements have increased the efficacy, safety, and stability of mAbs, making them more attractive for clinical use. There is a rising global prevalence of chronic diseases such as cancer, rheumatoid arthritis, and multiple sclerosis, where treatment with monoclonal antibodies has proven particularly effective. This increase in disease incidence has driven demand for targeted therapies that mAbs can provide. Overall, the monoclonal antibodies market is poised for continued growth and innovation, promising significant impacts on healthcare outcomes and offering substantial opportunities for pharmaceutical companies engaged in their development and commercialization.

The advent of next-generation antibody technologies has significantly enriched the therapeutic landscape. Innovations such as single-chain variable fragments (scFvs), nanobodies, bispecific antibodies, Fc-engineered antibodies, antibody biosimilars, antibody mimetics, and antibody-drug conjugates have all expanded the potential of mAbs in medicine. Today, antibody engineering has evolved to include a variety of formats beyond the traditional Y-shaped structure, such as single-domain antibodies (VHH), single-chain variable fragments (scFv), and antigen-binding fragments (Fab). These innovations expand the utility of antibodies in therapeutics by enhancing their specificity, reducing immunogenicity, and improving pharmacokinetics. The ability to modify antibodies through genetic engineering and mutagenesis has paved the way for the creation of fusion antibodies and other novel constructs designed to elicit enhanced immune responses, improve tissue penetration, and extend circulation half-lives. These capabilities have solidified monoclonal antibodies as a cornerstone of modern therapeutic strategies, particularly in treating complex diseases such as cancers and autoimmune disorders.

Select Competitors (Total 123 Featured) -
  • Abbott Diagnostics, Inc. - Core Laboratory
  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Global Economic Update
Monoclonal Antibodies - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Incidence of Chronic Diseases Strengthens Business Case for Monoclonal Antibody Therapies
Growing Awareness of the Benefits of Monoclonal Antibody Therapies Drives Adoption Across Various Medical Fields
Advances in Biotechnology Propel Growth of Monoclonal Antibodies Market
Increasing Adoption of Personalized Medicine Expands Addressable Market Opportunity for Monoclonal Antibodies
Growth in Cancer Treatment Generates Demand for Targeted Monoclonal Antibody Solutions
Innovations in Antibody Engineering Technology Spurs Market Growth for Monoclonal Antibodies
Focus on Immunotherapy Throws the Spotlight on Monoclonal Antibody Advancements
Expansion of Biopharmaceutical Manufacturing Sustains Growth in Monoclonal Antibodies Market
Integration of AI and Machine Learning in Drug Development Enhances Monoclonal Antibody Discovery
Technological Developments in Antibody-Drug Conjugates Propel Market Expansion for Monoclonal Antibodies
Emphasis on Reducing Treatment Costs Drives Adoption of Biosimilar Monoclonal Antibodies
Growth in Autoimmune Disease Treatment Spurs Use of Monoclonal Antibody Therapies
Adoption of Monoclonal Antibodies in Infectious Disease Management Expands Addressable Market Opportunity
Focus on Enhancing Efficacy and Safety Throws the Spotlight on Advanced Monoclonal Antibody Research
Increasing Use of Monoclonal Antibodies in Pediatric Care Accelerates Demand for Specialized Therapies
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Humanized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Humanized by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Humanized by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Human by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Human by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Chimeric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Chimeric by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Chimeric by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Murine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Murine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Murine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Autoimmune diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Autoimmune diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Autoimmune diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Infectious diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Infectious diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 36: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 37: World Monoclonal Antibodies Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: USA Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: USA 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: USA Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: USA 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
TABLE 47: Canada Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: Canada Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: Canada 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Canada 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 56: Japan Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Japan Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Japan 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 59: Japan Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Japan Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Japan 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 62: Japan Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 65: China Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: China Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: China 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 68: China Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: China Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: China 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 71: China Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 74: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Europe Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Europe 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 77: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: Europe Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Europe 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 80: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Monoclonal Antibodies by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 86: France Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: France Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: France 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 89: France Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: France Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: France 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 92: France Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 95: Germany Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: Germany Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Germany 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 98: Germany Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Germany Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Germany 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 101: Germany Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
TABLE 104: Italy Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Italy Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Italy 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 107: Italy Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Italy Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Italy 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 110: Italy Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 113: UK Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: UK Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: UK 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 116: UK Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: UK Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: UK 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 119: UK Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
SPAIN
TABLE 122: Spain Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: Spain Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: Spain 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 125: Spain Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: Spain Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: Spain 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 128: Spain Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Spain Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Spain 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
RUSSIA
TABLE 131: Russia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Russia Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Russia 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 134: Russia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Russia Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Russia 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 137: Russia Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Russia Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Russia 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Rest of Europe Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Rest of Europe 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Rest of Europe Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Rest of Europe 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of Europe Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of Europe 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Asia-Pacific Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Asia-Pacific Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 156: Asia-Pacific Historic Review for Monoclonal Antibodies by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 157: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 159: Asia-Pacific Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 160: Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
AUSTRALIA
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 161: Australia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 162: Australia Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 163: Australia 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 164: Australia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 165: Australia Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 166: Australia 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 167: Australia Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 168: Australia Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 169: Australia 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
INDIA
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 170: India Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 171: India Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 172: India 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 173: India Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 174: India Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 175: India 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 176: India Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 177: India Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 178: India 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 179: South Korea Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 180: South Korea Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 181: South Korea 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 182: South Korea Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 183: South Korea Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 184: South Korea 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 185: South Korea Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 186: South Korea Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 187: South Korea 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 189: Rest of Asia-Pacific Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 192: Rest of Asia-Pacific Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 195: Rest of Asia-Pacific Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
LATIN AMERICA
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 197: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 198: Latin America Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 199: Latin America 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 200: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 201: Latin America Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 202: Latin America 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 203: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 204: Latin America Historic Review for Monoclonal Antibodies by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 205: Latin America 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 206: Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 207: Latin America Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 208: Latin America 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 209: Argentina Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 210: Argentina Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 211: Argentina 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 212: Argentina Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 213: Argentina Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 214: Argentina 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 215: Argentina Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 216: Argentina Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 217: Argentina 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
BRAZIL
TABLE 218: Brazil Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 219: Brazil Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 220: Brazil 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 221: Brazil Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 222: Brazil Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 223: Brazil 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 224: Brazil Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 225: Brazil Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 226: Brazil 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
MEXICO
TABLE 227: Mexico Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 228: Mexico Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 229: Mexico 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 230: Mexico Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 231: Mexico Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 232: Mexico 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 233: Mexico Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 234: Mexico Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 235: Mexico 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 237: Rest of Latin America Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 238: Rest of Latin America 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 240: Rest of Latin America Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 241: Rest of Latin America 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 243: Rest of Latin America Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 244: Rest of Latin America 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
MIDDLE EAST
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 245: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 246: Middle East Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 247: Middle East 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 248: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 249: Middle East Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 250: Middle East 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 251: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 252: Middle East Historic Review for Monoclonal Antibodies by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 253: Middle East 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 254: Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 255: Middle East Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 256: Middle East 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
IRAN
TABLE 257: Iran Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 258: Iran Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 259: Iran 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 260: Iran Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 261: Iran Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 262: Iran 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 263: Iran Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 264: Iran Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 265: Iran 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
ISRAEL
TABLE 266: Israel Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 267: Israel Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 268: Israel 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 269: Israel Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 270: Israel Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 271: Israel 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 272: Israel Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 273: Israel Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 274: Israel 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 276: Saudi Arabia Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 277: Saudi Arabia 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 279: Saudi Arabia Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 280: Saudi Arabia 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 282: Saudi Arabia Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 283: Saudi Arabia 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 284: UAE Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 285: UAE Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 286: UAE 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 287: UAE Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 288: UAE Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 289: UAE 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 290: UAE Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 291: UAE Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 292: UAE 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 294: Rest of Middle East Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 295: Rest of Middle East 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 297: Rest of Middle East Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 298: Rest of Middle East 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 300: Rest of Middle East Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 301: Rest of Middle East 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
AFRICA
Monoclonal Antibodies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 302: Africa Recent Past, Current & Future Analysis for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 303: Africa Historic Review for Monoclonal Antibodies by Indication - Cancer, Autoimmune diseases, Infectious diseases and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 304: Africa 16-Year Perspective for Monoclonal Antibodies by Indication - Percentage Breakdown of Value Sales for Cancer, Autoimmune diseases, Infectious diseases and Other Indications for the Years 2014, 2024 & 2030
TABLE 305: Africa Recent Past, Current & Future Analysis for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 306: Africa Historic Review for Monoclonal Antibodies by Source - Human, Humanized, Chimeric and Murine Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 307: Africa 16-Year Perspective for Monoclonal Antibodies by Source - Percentage Breakdown of Value Sales for Human, Humanized, Chimeric and Murine for the Years 2014, 2024 & 2030
TABLE 308: Africa Recent Past, Current & Future Analysis for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 309: Africa Historic Review for Monoclonal Antibodies by End-Use - Hospitals, Research Institutes and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 310: Africa 16-Year Perspective for Monoclonal Antibodies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Research Institutes and Other End-Uses for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings